Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-17
2011-11-22
Morris, Patricia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S272700
Reexamination Certificate
active
08063076
ABSTRACT:
The present invention relates to the mono-sulfate salt, crystalline forms A and B of the mono-sulfate salt, an amorphous form of the mono-sulfate salt, hemi-sulfate salts, and a crystalline form A of the hemi-sulfate salt of the compound 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine.
REFERENCES:
patent: 3303199 (1967-02-01), Doebel et al.
patent: 3341548 (1967-09-01), Hoffer
patent: 4352818 (1982-10-01), Hunkeler et al.
patent: 4508560 (1985-04-01), Brunner et al.
patent: 4711962 (1987-12-01), Leone-Bay
patent: 6627646 (2003-09-01), Bakale et al.
patent: 7091222 (2006-08-01), Buettelmann et al.
patent: 7153874 (2006-12-01), Buettelmann et al.
patent: 2004/0259917 (2004-12-01), Cosford et al.
patent: 2035905 (1972-02-01), None
patent: 059 390 (1982-09-01), None
patent: WO 91/00277 (1991-01-01), None
patent: WO 99/02497 (1999-01-01), None
patent: WO 99/08678 (1999-02-01), None
patent: WO 01/16121 (2001-03-01), None
patent: WO 02/08205 (2002-01-01), None
patent: WO 02/46166 (2002-06-01), None
patent: WO 2004/080998 (2004-09-01), None
patent: WO 2004/108701 (2004-12-01), None
patent: WO 2005/003117 (2005-01-01), None
patent: WO 2005/023795 (2005-03-01), None
patent: WO 2005/118568 (2005-12-01), None
U.S. Pharmacopia #23, National Formulary #18, 1995, 1843-1844.
Concise Encyclopedia Chemistry, NY: Walter de Gruyter, 1993, 872-873.
Muzaffar et al., “Polymorphism and Drug Availability, etc.,” J of Pharm. (Lahore), 1979, 1(1), 59-66.
Jain et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6) 315-329.
Taday et al., “Using Terahertz, etc.,” J of Pharm. Sci., 92(4), 2003, 831-838.
Doelker, english translation of Ann. Pharm. Fr., 2002, 60: 161-176, pp. 1-39.
Doelker, english translation of S.T.P, Pratiques (1999), 9(5), 399-409, pp. 1-33.
Otuska et al., “Effect of Polymorphic, etc.,” Chem. Pharm. Bull., 47(6) 852-856 (1999).
CMU Pharmaceutical polymorphism, internet, p. 1-3 (2002) (print out Apr. 3, 2008).
Singhal et al., “Drug Polymorphism, etc.,” Advanced Drug Delivery reviews 56, p. 335-347 (2004).
Sakamoto et al., Chem. Pharm. Bull., vol. 35(2) pp. 823-828 (1987).
Miller, et al., Chem. Mater., vol. 6(7) pp. 1023-1032 (1994).
Bond et al., Synth. Commun., vol. 19, pp. 2551-2566 (1989).
Sintas et al., Journal of Labelled Compds. & Radiopharmaceuticals, 39, pp. 677-684 (1997).
Hoffer et al., J. Med. Chem., vol. 17(9) pp. 1019-1020 (1974).
Ohba et al. Chem. Pharm. Bull. vol. 42, pp. 1784-1790 (1994).
Kulkarni et al., Aust. J. Chem. vol. 40(8) pp. 1399-1413 (1987).
Vasileuskii et al., Bull. Acad. Sci. USSR Div. Chem. Sci. pp. 626-(1983).
Laronde et al., Inorg. Chim. Acta, vol. 296(1), pp. 208-221 (1999).
Shafiee et al., J. Heterocyclic Chem. vol. 33, pp. 671-673 (1996).
Shafiee et al., J. Heterocyclic Chem. vol. 35, pp. 607-610 (1998).
Ivanova et al. Chem. Heterocycl. Comp. vol. 36(2), pp. 221-222 (2000).
Wadsworth, G. H., J. Chem. Soc. vol. 57, pp. 8-12 (1890).
Cornforth et al., J. Chem. Soc. pp. 1085-1087 (1952).
Ross et al., J. Med. Chem. vol. 15(10) pp. 1035-1040 (1972).
Kiyomori et al., Tetrahedron Lett. vol. 40: pp. 2657-2660 (1999).
Tohda et al., Synthesis pp. 777-778 (1977).
Cliff et al., Synthesis pp. 681-682 (1994).
Ohira, Synth. Comm. 19: pp. 561-564 (1989).
Collman et al., Org. Lett. 2: pp. 1233-1236 (2000).
Schlaeger et al., Cytotechnology 30: pp. 71-83 (1999).
Porter et al., Br. J. Pharmacol. 128: pp. 13-20 (1999).
Millan, Progress in Neurobiology 70: pp. 83-244 (2003).
Abstract corresponding to DE 2035905 (Document B6).
Fabrizio Gasparini et al., Neuropharmacology Pergamon Press, XP001032948, vol. 38, No. 10 pp. 1493-1503 (1999).
Will P.J.M. Spooren et al., Trends in Phrmacological Sciences, Elsevier Trends Journal, XP004247865, vol. 22, No. 7, pp. 331-337 (2001).
Arena, et al., Journal of Medicinal Chem. American Chem. Society, XP001005697, vol. 18, No. 11, pp. 1147-1150 (1975).
Mutel, Expert Opin. Ther. Patents, vol. 12, pp. 1845-1852 (2002).
Storto et al., European Journal of Pharmacology (2004), vol. 497(1 pp. 25-27.
Storto et al., Journal of Hepatology (2003) vol. 38(2), pp. 179-187.
Storto et al., Hepatology (Philadelphia) (2000), vol. 31(3), pp. 649 655.
Lynch, et al., Expert Opin. Ther. Patents (2002) vol. 12, pp. 11-27.
Cleary Thomas
Glomme Alexander
Grassmann Olaf
Kuang Shan-Ming
Meier Roland
Hoffmann-La Roche Inc.
Johnston George W.
Morris Patricia
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Solid forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solid forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid forms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4303305